The University of Kansas Cancer Center-South

Clinical research site in Kansas City, Missouri

Part of University of Kansas Medical Center

As of July 2026, 1 paid clinical trial is recruiting at The University of Kansas Cancer Center-South in Kansas City, Missouri. Active studies at this site cover conditions such as Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 and Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at The University of Kansas Cancer Center-South (1)

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

221 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT01810913·Phase 2, Phase 3·Recruiting·Listed Mar 2013

Apply to this trial

Explore more

Paid clinical trials in Kansas City, MO · Missouri clinical trials

The University of Kansas Cancer Center-South

Recruiting clinical trials at The University of Kansas Cancer Center-South (1)

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

More research sites in Kansas City

Explore more